Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y, Adachi S, Kashiwagi H, Fukao K, Ohara K
Department of Surgery and Radiology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-shi, Japan.
Hepatogastroenterology. 1999 May-Jun;46(27):1585-91.
BACKGROUND/AIMS: The efficacy of combining resection and radiation in the management of advanced gallbladder cancer has not yet been defined. In this study, effects of combining radiation therapy on survival, local control and the pattern of recurrences were analyzed as a retrospective review.
From October 1976 to May 1996, 85 patients with stage IV (pTNM) gallbladder cancer underwent various aggressive resection modalities in our institute, including 34 liver resections, 30 hepatopancreaticoduodenectomies. Intra-operative, external or intracavitary radiation therapy was supplemented to resection in 47 patients.
The 30-day operative mortality rate was 5.9% and the overall 5-year survival rate of stage IV disease patients was 6.3%; 3 patients are living well more than 6 years after surgery. Adjuvant radiotherapy yielded a significantly (p=0.0023) higher 5-year survival rate (8.9%) than resection alone (2.9%). The local control rate was significantly (p=0.0467) higher in the adjuvant radiation group than in the resection alone group (59.1% vs. 36.1%). However, there was no statistical difference in the frequency of distant metastasis between the two groups. Significant improvement (p=0.0028) of long-term survival was exhibited when radiation was used appropriately on patients with microscopic residues only. Those with macroscopic or without microscopic residues failed to improve. The 5-year survival rate and median survival time of patients receiving adjuvant radiation therapy for microscopic residues were 17.2% and 463 days, respectively.
Adjuvant radiation therapy following aggressive resection, in certain circumstances, improves prognosis with acceptable operative mortality for stage IV gallbladder cancer.
背景/目的:手术切除与放疗联合治疗晚期胆囊癌的疗效尚未明确。本研究通过回顾性分析,探讨了放疗联合治疗对晚期胆囊癌患者生存、局部控制及复发模式的影响。
1976年10月至1996年5月,我院85例IV期(pTNM)胆囊癌患者接受了多种根治性手术,包括34例肝切除术、30例胰十二指肠切除术。47例患者在手术中、术后接受了术中、体外或腔内放疗。
30天手术死亡率为5.9%,IV期患者总体5年生存率为6.3%;3例患者术后存活超过6年。辅助放疗组5年生存率(8.9%)显著高于单纯手术组(2.9%)(p = 0.0023)。辅助放疗组局部控制率显著高于单纯手术组(59.1%对36.1%,p = 0.0467)。然而,两组远处转移发生率无统计学差异。仅对镜下残留患者合理应用放疗,可显著提高长期生存率(p = 0.0028)。镜下或肉眼残留患者未能从中获益。镜下残留患者接受辅助放疗后的5年生存率和中位生存时间分别为17.2%和463天。
对于IV期胆囊癌患者,在根治性手术后辅以放疗,在一定情况下可改善预后,且手术死亡率可接受。